Tofersan, an antisense oligonucleotide (ASO) therapy that was approved for SOD1 variant ALS patients in 2023, established the feasibility of delivering therapies targeting pathogenic variants that drive this rapid neurodegeneration [17]. Here, SOD1 is linked to amyotrophic lateral sclerosis.